This version of the guidelines (version 4.0), includes the following recommendations: 1) a strong recommendation for mask use in community settings in higher risk situations; 2) a conditional recommendation to encourage a risk-based approach for mask use in community settings in situations that do not fall within the scope of the strong recommendation; 3) a good practice statement advising individuals with signs and symptoms suggestive of COVID-19 or those who test positive for COVID-19 to wear a medical mask when interacting with others in or outside of one’s household or sharing space with others; and 4) amendment of an existing good practice statement on the implementation of policies to reduce SARS-CoV-2 transmission to promote the revisiting and strengthening of PHSM as new evidence arises. The strong and conditional recommendations for mask use in the community complement each other, outlining possible scenarios in which masks may benefit the wearer. As some situations (see strong recommendation) necessitate mask wearing for maximum protection, others (see conditional recommendation) may be better suited for a risk-based approach.

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• epidemický výskyt choroby MeSH
• kontrola infekce MeSH
• koronavirové infekce MeSH
• masky MeSH
• osobní ochranné prostředky MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• infekční lékařství
• veřejné zdravotnictví
• NLK Publikační typ
• publikace WHO

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• delfská metoda MeSH
• dítě MeSH
• epidemický výskyt choroby MeSH
• konsensus MeSH
• mladiství MeSH
• postakutní syndrom COVID-19 MeSH
• SARS-CoV-2 MeSH
• Check Tag
• dítě MeSH
• mladiství MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• infekční lékařství
• NLK Publikační typ
• publikace WHO

• MeSH
• anonymizace dat MeSH
• epidemický výskyt choroby MeSH
• sběr dat MeSH
• virus Ebola MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• infekční lékařství
• veřejné zdravotnictví
• NLK Publikační typ
• publikace WHO

This document summarizes current WHO guidance for public health surveillance of coronavirus disease 2019 (COVID-19) in humans caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The global goals to end the COVID-19 emergency are to reduce SARS-CoV-2 transmission and the impact of COVID-19 disease. Surveillance remains fundamental to understanding the evolution of the virus, the risk factors for severe disease and the impact of vaccination and public health and social measures. WHO continues to recommend maintaining and strengthening surveillance to achieve the core surveillance objectives for COVID-19 such as early warning for changes in epidemiological patterns, monitoring trends in morbidity and mortality, monitoring burden of disease on health care capacity and incorporating strategic and geographically representative genomic surveillance.

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• epidemický výskyt choroby MeSH
• epidemiologické monitorování MeSH
• ochrana veřejného zdraví MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• infekční lékařství
• NLK Publikační typ
• publikace WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• epidemický výskyt choroby MeSH
• vakcíny proti COVID-19 MeSH
• Publikační typ
• směrnice MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• infekční lékařství
• preventivní medicína
• NLK Publikační typ
• publikace WHO

Routine diagnostic surveillance for COVID-19 has been augmented with environmental surveillance (ES) in wastewater in many locations. ES provides additional evidence on virus in circulation at population level including presence or absence, early warning of increasing or decreasing trends, and information on variants of concern or interest. This guidance is targeted at public health officials who want to understand and integrate complementary ES into COVID-19 control strategies.

• MeSH
• Betacoronavirus MeSH
• COVID-19 diagnóza   epidemiologie   MeSH
• epidemický výskyt choroby MeSH
• monitorování životního prostředí MeSH
• ochrana veřejného zdraví MeSH
• SARS-CoV-2 MeSH
• testování na COVID-19 MeSH
• Publikační typ
• směrnice MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• environmentální vědy
• infekční lékařství
• NLK Publikační typ
• publikace WHO

The aim of the document is to identify and articulate salient ethical considerations regarding mandatory vaccinations against COVID-19. This document updates a policy brief initially published in April 2021 in response to changes in the COVID-19 vaccine landscape, including authorization of vaccines for children and additional information about, and experiences with, vaccination mandates for COVID-19.

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• epidemický výskyt choroby MeSH
• etika MeSH
• vakcinace MeSH
• vakcíny proti COVID-19 MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• etika, bioetika, lékařská etika
• preventivní medicína
• NLK Publikační typ
• publikace WHO

COMIRNATY® (10 micrograms/dose), also known as paediatric Pfizer-BioNTech COVID-19 vaccine, is a messenger RNA (mRNA) based vaccine against coronavirus disease 2019 (COVID-19) for children from 5 years to 11 years of age. The mRNA instructs the cell to produce proteins of the S antigen (a piece of the spike protein unique to SARS-CoV-2) to stimulate an immune response. As COMIRNATY® does not contain the virus to produce immunity the vaccine cannot give the child COVID-19.

• MeSH
• COVID-19 MeSH
• vakcíny proti COVID-19 MeSH
• vakcíny MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• preventivní medicína
• pediatrie
• NLK Publikační typ
• publikace WHO

These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes.

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• epidemický výskyt choroby MeSH
• vakcíny proti COVID-19 MeSH
• Publikační typ
• směrnice MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• infekční lékařství
• preventivní medicína
• NLK Publikační typ
• publikace WHO

These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes.

• MeSH
• Betacoronavirus MeSH
• COVID-19 MeSH
• epidemický výskyt choroby MeSH
• vakcíny proti COVID-19 MeSH
• vakcíny MeSH
• Publikační typ
• směrnice MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví
• infekční lékařství
• preventivní medicína
• NLK Publikační typ
• publikace WHO